915095-85-1

Basic information

• Product Name: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone
• Synonyms: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone;Methanone, [5-Bromo-2-Chloro-phenyl](4-Fluoro Phenyl);Bromo fuloro benzone
• CAS NO: 915095-85-1
• Molecular Formula: C₁₃H₇BrClFO
• Molecular Weight: 313.5494832
• EINECS: -0
• Mol File: 915095-85-1.mol

Chemical Properties

• Boiling Point: 390.6±37.0 °C(Predicted)
• Appearance: /
• Density: 1.568±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone(CAS DataBase Reference)
• NIST Chemistry Reference: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone(915095-85-1)
• EPA Substance Registry System: (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone(915095-85-1)

Safety Data

• Hazardous Substances Data: 915095-85-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone is utilized as an intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs with diverse therapeutic applications.
Used in Agrochemical Synthesis:
In the agrochemical industry, (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone serves as an intermediate for the production of agrochemicals, which are essential for crop protection and enhancement of agricultural yields.
Used in Antibacterial Applications:
(5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone has been studied for its antibacterial properties, making it a potential candidate for use in the development of new antimicrobial agents to combat bacterial infections.
Used in Antifungal Applications:
Similarly, (5-bromo-2-chlorophenyl)(4-fluorophenyl)methanone has demonstrated antifungal properties, indicating its potential use in the creation of antifungal agents to address fungal infections and related health issues.

Upstream product

• 403-43-0 4-fluorobenzoyl chloride 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 462-06-6 fluorobenzene 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 

Downstream Products

• 915095-99-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)tetrahydro-2H-pyran-3,4,5-trityl triacetate 
• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 
• 864070-44-0 empagliflozin 

Relevant articles and documents

Preparation method of polysubstituted diphenyl ketone

The preparation method comprises the following steps: (1) a compound represented by the formula II and a compound shown III as a raw material; and synthesizing the compound as shown IV. (2) The compound of Formula IV is subjected to Fries rearrangement to produce a compound of Formula V. (3) A compound of Formula V is subjected to a halogenation reaction in contact with a halogenation reagent to prepare a multi-substituted diphenyl ketone represented by Formula I. Wherein, X is selected from H, F, Cl, Br, I. R1 Selected H from F Cl, Br I are RO selected R from H, C1 - C6. X is selected from F, Cl, Br, and i. The present invention is capable of improving the yield and selectivity of the target product.

Preparation method of 2-hydroxybenzophenone compound and halogenated derivative thereof

The invention relates to the field of pharmaceutical synthesis, in particular to a preparation method of a 2-hydroxybenzophenone compound and a halogenated derivative thereof, and the preparation method of the 2-hydroxybenzophenone compound is as follows: under the action of lewis acid, para-substituted anisole and para-substituted benzoyl chloride are subjected to acylation reaction and demethylation reaction to obtain the 2-hydroxybenzophenone compound. The preparation method of the halogenated derivative of the 2-hydroxybenzophenone compound comprises the following steps: firstly, preparing the 2-hydroxybenzophenone compound by the method, and then carrying out halogenation reaction by a halogenation reagent to obtain the halogenated derivative of the 2-hydroxybenzophenone compound. According to the method, impurities which are difficult to separate and obtained in the preparation process can be effectively reduced, so that the purity of the prepared 2-hydroxybenzophenone compound and the halogenated derivative thereof is improved.

A NEW HETEROCYCLIC COMPOUND: CRYSTAL STRUCTURE AND ANTICANCER ACTIVITY AGAINST HUMAN LUNG ADENOCARCINOMA CELLS

Abstract: New heterocyclic compound (S)-3-(4-(5-bromo-2-chlorobenzyl)phenoxy)tetrahydrofuran (1), designed by utilizing 5-bromo-2-chlorobenzoic acid (2) as the starting material, is obtained by the organic synthesis and then characterized by single crystal X-ray crystallography, 1H NMR and IR spectroscopy. In the biological study, the CCK-8 assay is performed to evaluate the inhibitory effect of the compound on SPC-A-1 human lung adenocarcinoma cells in vitro by measuring the cancer cell viability. Then, the anticancer activity of the compound is also confirmed by the in vivo xenograft experiment by measuring the mice body weight and the cancer volume.

Synthetic method of empagliflozin

The invention provides a brand-new synthesis process of empagliflozin. According to the process, a boric acid ester is used for halogen removal, and specific reaction conditions are combined, so thatempagliflozin can be prepared with high yield and simplicity and convenience in operation. The synthesis method of empagliflozin has the advantages of mild reaction conditions, high total yield, few side reactions and convenience in operation, thereby being beneficial to industrial production and cost control.

Synthetic method for preparing empagliflozin intermediate

The invention discloses a synthetic method for preparing an empagliflozin intermediate. The method comprises the following specific steps: 1) mixing a compound I with a solvent, preparing a compound II by using an acylation reagent, adding the compound II into a system of fluorobenzene and aluminum trichloride, carrying out a Friedel-Crafts reaction at room temperature, performing quenching with water, conducting liquid separation and washing successively, and concentrating an organic matter to obtain a compound III; 2) adding the compound III into a reaction kettle, adding a solvent, an alkali and a catalyst, then adding a compound IV, carrying out heating for a reaction, performing washing with water after the reaction, and conducting concentrating and crystallizing to obtain a solid compound V; and 3) adding the compound V into the reaction kettle, adding a solvent, an acid and a reducing agent, carrying out quenching with water after a reaction, conducting liquid separation and washing successively, concentrating an organic matter, and carrying out crystallizing to obtain a solid compound V. The method is simple and safe in process, high in product yield, easy in impurity control and suitable for industrial production.

A SGLT2 inhibitor intermediates preparation method (by machine translation)

The invention discloses a SGLT2 inhibitor intermediates preparation method, comprises the following steps: (1) 5 - halo - 2 - chlorobenzoic acid and fluorobenzene to Friedel-crafts reaction, to obtain (5 - halo - 2 - chlorophenyl) (4 - fluorophenyl) a ketone; (2) under the action of the inorganic base, (5 - halo - 2 - chlorophenyl) (4 - fluorophenyl) methanone and ethanol undergo the substitution reaction, after the reaction is finished after treatment to obtain (5 - halo - 2 - chlorophenyl) (4 - ethoxy) a ketone; (3) (5 - halo - 2 - chlorophenyl) (4 - ethoxy) methanone in the reducing agent under the effect of the reduction reaction of carbonyl, get said SGLT2 inhibitor intermediates. The preparation method is through adopting the inorganic alkali and ethanol instead of the ethoxide reagent and DMSO (or DMF), not only can effectively reduce the cost, but also more environmentally friendly. (by machine translation)

C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF

This invention relates to a kind of C-aryl glycoside derivatives, its pharmaceutical compositions, preparation methods, and uses thereof. The preparation method comprises: method 1: in a solvent, deprotecting the acetyl protecting groups of compound 1-f in the presence of a base; method 2: 1) compound 2-g reacts with via Mitsunobu reaction; 2) deprotecting the acetyl protecting groups of compound 2-f obtained from step 1; method 3: 1) compound 2-g reacts with via nucleophilic substitution reaction; 2) deprotecting the acetyl protecting groups of compound 3-f obtained from step 1. The pharmaceutical composition comprises a kind of C-aryl glycoside derivatives; it's pharmaceutically acceptable salts and/or prodrugs thereof and excipient thereof. This invention further relates to a kind of C-aryl glycoside derivatives, it's pharmaceutically acceptable salts or pharmaceutical compositions thereof for the use in preparation of a SGLT inhibitor. The C-aryl glycoside derivatives of this invention provides a new direction for the study of SGLT inhibitors.

Preparation method of SGLT2 inhibitor intermediate

The invention provides a preparation method of an SGLT2 inhibitor intermediate II. The preparation method includes that a compound V and an ethoxide reagent are subjected to nucleophilic substitution in a proper solution to obtain a compound II, wherein the compounding formula is shown as below, and X in the compound V structure is selected from Br or I. By the compounding route, the problem of purification difficulty caused by plenty of isomers in compounding routes in documentary reports is solved. Reaction operations are simple and convenient, the reagent is low in cost and easy to get, and the obtained product does not contain the isomers. The route is suitable for industrial production.

PROCESS FOR THE PREPARATION OF EMPAGLIFLOZIN

An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protecting groups.

Efficient synthesis of empagliflozin, an inhibitor of SGLT-2, utilizing an AlCl3-promoted silane reduction of a β-glycopyranoside

An efficient production synthesis of the SGLT-2 inhibitor Empagliflozin (5) from acid 1 is described. The key tactical stage involves I/Mg exchange of aryl iodide 2 followed by addition to glucono lactone 3 in THF. Subsequent in situ treatment of the resulting lactol with HCl in MeOH produces β-anomeric methyl glycopyranoside 4 which is, without isolation, directly reduced with Et3SiH mediated by AlCl3 as a Lewis acid in CH 2Cl2/MeCN to afford 5 in 50% overall yield. The process was implemented for production on a metric ton scale for commercial launch.